Connect with us

Business

Ibogaine For Addiction: 5 Reasons Why It’s Safer To Do It In A Hospital

Published

on

As it is a complex medical intervention, with physical and psychological effects, the use of ibogaine for detoxification requires the presence of qualified doctors and mental health professionals to provide treatment.

Ibogaine is a substance extracted from the root of the iboga, a shrub that grows in West Africa. For thousands of years, it has been used by indigenous cultures for healing rituals. Since the 1960s, a series of studies have been carried out, both in animals and in humans, which have shown its properties to reduce the withdrawal syndrome to opiates and other substances that cause addiction.

Current scientific evidence confirms that ibogaine has potentially useful effects to treat chemical dependency, which is why various clinics worldwide have begun to offer this type of therapy. However, it must be taken into account that it is a drug with a high level of toxicity and that its irresponsible intake carries risks for the patient that can even mean death. It is for this reason that it is essential, to guarantee your safety, that the provision of these treatments is carried out in environments equipped with an infrastructure and a team of suitable professionals, according to the standards of modern medicine.

Here are five reasons why ibogaine-based addiction treatments should be done in hospital settings.

  1. Need To Perform The Intervention In A Safe And Legal Environment, With The Necessary Medical Equipment And Infrastructure
  2. Need For Prior Medical And Psychological Examinations To Determine Contraindications
  3. The Hospital Environment Contributes To The Physical Preparation Prior To The Session
  4. Carrying Out The Session In A Hospital Environment Allows Adequate Monitoring By Health Professionals To Avoid Or Reduce The Side Effects of Ibogaine
  5. Need For Therapeutic Follow-up After The Session To Integrate The Treatment And Avoid Relapses

Ibogaine exerts its action directly on the Central Nervous System, causing physical and psychological effects on the body. Its high level of toxicity carries with it some dangers associated with the dose and the context in which it is ingested. It is for this reason that it is essential that the sessions are carried out in a pleasant environment and capable of guaranteeing patient support. This must have adequate infrastructure (spacious and clean facilities), as well as the necessary medical supplies (cardiac monitoring devices and defibrillators) so that the treatment is safe.

It is also of great importance that the center where the session is held adheres to the ethical codes and established medical protocols. Some providers often offer these therapies clandestinely and illegally in unregulated settings, which carries considerable risks. It should be considered that, internationally, the medicinal use of ibogaine is prohibited in several countries.

The therapies assisted by this substance to treat patients with addiction are legal, however, in some Latin American countries. In Mexico, for example, there are several private centers that legally offer this type of therapy, although state regulations in this country do not require that they be carried out in hospital settings. For its part, in Brazil, ibogaine is neither registered nor prohibited, its importation and use being legal since 2013 as long as the patient has a medical prescription. A decree of the state of Sao Paulo in 2016 requires that treatments based on the intake of ibogaine must be carried out under medical supervision and in hospital settings. These types of regulations are essential to ensure the safe and legal use of ibogaine.

Need For Prior Medical And Psychological Examinations To Determine Contraindications

It is highly probable, due to the high toxicity of ibogaine, that its intake may have unwanted effects on the functioning of the organism, mainly the Cardiac System. It is for this reason that it is usually contraindicated in patients with cardiovascular problems. Before carrying out the treatment, it is necessary for the patient to undergo a thorough medical examination to determine if it will be risky or not. Each case must be analyzed by a qualified doctor who determines if the patient meets the necessary physical conditions to start the session.

doctor patient
Photo by Thirdman via Pexels

Ibogaine is also contraindicated in patients with psychiatric disorders such as schizophrenia, psychosis, bipolar disorder, or borderline personality disorder. Carrying out psychological or psychiatric examinations prior to the start of treatment is, therefore, of great importance. The mental health professional in charge of these check-ups must evaluate the presence of these disorders and their severity in order to establish whether the patient is able to resist treatment without complications.

It is from these studies that the professionals in charge will determine whether or not it is risky to carry out the treatment and, if they decide that it is pertinent to do so, they will take the necessary precautions to reduce the possible risks during the session.

The Hospital Environment Contributes To The Physical Preparation Prior To The Session

Ibogaine is a powerful drug whose effects can cause a physically intense experience for the patient. It is for this reason that, the better the physical condition of the latter, the more intervention will be safer and more efficient. Generally, doctors recommend good hydration, a careful diet, based on healthy foods, and the intake of vitamin and mineral supplements. Likewise, it is recommended to stop consuming water and fast a few hours before the session, since it is difficult to have to go to the bathroom during the session due to the ataxia induced by ibogaine intake.

On the other hand, it is essential that weeks before and during the administration of the treatment, the patient avoids the consumption of any type of psychoactive. Indeed, the interaction of certain drugs with ibogaine could increase cardiac risks, even causing death. It is for this reason that many centers tend to carry out a guided detoxification process sometime before ingestion, thus increasing the safety of the session considerably.

Carrying Out The Session In A Hospital Environment Allows Adequate Monitoring By Health Professionals To Avoid Or Reduce The Side Effects of Ibogaine

Therapeutic interventions based on the intake of ibogaine are often controversial due to the risks they entail. Among the most frequent side effects are the presence of dizziness, nausea, vomiting, motor coordination difficulties, and tachyarrhythmias.

It can be inferred, therefore, that it is necessary for the sessions to be monitored by highly qualified health professionals who carry out an adequate follow-up to avoid or reduce possible unwanted damage induced by ibogaine. It is important that, during the sessions, the instructions of the doctor in charge are followed, who must adequately inform the patient about the possible adverse effects and dispel their doubts in the event that there are any. The presence of nurses or caregivers is usually recommended after the end of the experience. Carrying out the intake in a hospital environment will ensure the presence of health professionals for proper follow-up.

Legal MDMA-Assisted Therapy Is Likely Within Next Couple Years
Photo by Pornpak Khunatorn/Getty Images

As it is a complex medical intervention, with physical and psychological effects, the use of ibogaine for detoxification requires, in addition to the presence of qualified doctors to provide the treatment, the support of mental health professionals, such as psychiatrists, psychologists, or psychotherapists. This is of great importance because not all patients manage to deal with the introspective experience produced by ibogaine, and may suffer episodes of anxiety and paranoia. Personalized follow-up by these professionals will reduce the side effects of ibogaine on the patient’s psyche and improve the intake experience.

Need For Therapeutic Follow-up After Session To Integrate  Treatment And Avoid Relapses

The intake of ibogaine is an instance of a larger therapeutic process. It is for this reason that it is important to maintain the necessary aftercare to carry out the treatment successfully. The design of a care plan after the session constitutes an essential part of the treatment and must be monitored by the team of professionals in charge of it. Generally, it is recommended that the centers in which the treatment is applied offer a plan of continued care after the session or, at least, articulate and collaborate with other therapeutic centers in charge of offering this care.

Psychological support is a key factor in guaranteeing the success of treatment. During the session and the days that follow, patients usually undergo a process of considerable psychological changes and personal redefinition, which is why it is of great importance that they have the support of mental health professionals to gradually return to their daily lives.

Likewise, it is necessary that the post-session follow-up by the medical team focuses on avoiding relapses. It should be considered that once ingested, the tolerance to the substance that generated addiction in the patient tends to be much lower than before. This means that the usual doses that he was used to could have more severe effects on the body and even cause an overdose. Having a relapse does not mean that the therapeutic process itself has been useless; in some cases, professionals evaluate, the application of a second dose to improve the recovery process.

Source: https://thefreshtoast.com/cannabis/ibogaine-for-addiction-5-reasons-why-its-safer-to-do-it-in-a-hospital/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News